Johnson Fistel Begins Investigation into Cardlytics Following a Significant Drop in the Company’s Stock
Shareholder rights law firm Johnson Fistel, LLP is investigating whether Cardlytics, Inc. (NASDAQ: CDLX) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased Cardlytics securities? If you purchased securities and suffered losses on your investment, join our investigation now:
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
What is Johnson Fistel investigating? On August 7, 2024, Cardlytics announced its second quarter 2024 financial results, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors. Following this news, Cardlytics stock was trading down 56% during pre-market trading on August 8, 2024.
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.